{"classes":[{"categories":[{"measurements":[{"comment":"Although samples were collected for 26 participants, CL/F could not be evaluated because extrapolated AUC was over 20% for all participants. CL/F is derived from extrapolated AUC. However, when it is over 20% for all participants, CL/F cannot be determined.","groupId":"OG000","spread":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"CL/F is the apparent total body clearance of asciminib from plasma after oral administration (volume x time-1).","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Patients took asciminib 80 mg QD under fasting conditions on ongoing basis.","id":"OG000","title":"Asciminib (All Asciminib)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Although samples were collected for 26 participants, CL/F could not be evaluated because extrapolated AUC was over 20% for all participants. CL/F is derived from extrapolated AUC. However, when it is over 20% for all participants, CL/F cannot be determined.","reportingStatus":"POSTED","timeFrame":"Week 2 (0 hours (h) pre-dose, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose)","title":"PK of Asciminib: CL/F","type":"SECONDARY","unitOfMeasure":"ng*hr/mL"}